Moderna/Merck mRNA vaccine trial was for melanoma.
Results 'promising' results P2. 44% reduced recurrence compared to Keytruda mono.
Check out Immutep/Merck TACTI-Mel P1 trial. Oct 2018
Efti and Keytruda
Results promising too (small cohort 24 patients).
Disease control - 66%
Patients tumour shrinkage - 50%
NB - melanoma is particularly immuno-responsive and a crowded space for approved therapies.
Poster presentation of TACTI-mel
Conclusion section:-
2 patients with complete response
Supports hypotheses that combining APC activator with checkpoint inhibitor- synergy and clinical benefit
Further investigation of this combination is ongoing in NSCLC and HNSCC
Therefore focus moved to NSCLC/HNSCC as higher priority unmet need.
Efti - APC activator could be the idea partner to help turn 'cold' solid tumours 'hot' and boost performance of primary ICI's, chemo and others, including vaccine/virus drug candidates in clinical development.
Lag-3 and efti is only at the beginning of its commercial journey.
- Forums
- ASX - By Stock
- IMM
- Overnight Market report
Overnight Market report, page-1254
-
- There are more pages in this discussion • 1,606 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
33.5¢ |
Change
-0.010(2.90%) |
Mkt cap ! $479.3M |
Open | High | Low | Value | Volume |
34.0¢ | 34.0¢ | 32.5¢ | $799.1K | 2.402M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
23 | 318524 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 179588 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
41 | 214555 | 0.325 |
21 | 266934 | 0.320 |
11 | 159820 | 0.315 |
6 | 117351 | 0.310 |
6 | 127536 | 0.305 |
Price($) | Vol. | No. |
---|---|---|
0.330 | 188975 | 36 |
0.335 | 196398 | 11 |
0.340 | 543349 | 11 |
0.345 | 240113 | 11 |
0.350 | 708314 | 10 |
Last trade - 15.35pm 27/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |